rocaltrol 0.25 mikrog
atnahs pharma netherlands b.v. - kalsitriol - kapsel, myk - 0.25 mikrog
rocaltrol 0.25 mikrog
2care4 aps - kalsitriol - kapsel, myk - 0.25 mikrog
rocaltrol 0.25 mikrog
2care4 aps - kalsitriol - kapsel, myk - 0.25 mikrog
rocaltrol 0.25 mikrog
2care4 aps - kalsitriol - kapsel, myk - 0.25 mikrog
silkis 3 mikrog/ g
galderma nordic ab - kalsitriol - salve - 3 mikrog/ g
calcipotriol/betamethasone aristo 50 mikrog/ g / 0.5 mg/ g
aristo pharma gmbh - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g
calcipotriol/betamethasone orifarm 50 mikrog/ g / 0.5 mg/ g
orifarm generics a/s - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g
calcipotriol/betamethasone sandoz 50 mikrog/ g / 0.5 mg/ g
sandoz - københavn - kalsipotriolmonohydrat / betametasondipropionat - salve - 50 mikrog/ g / 0.5 mg/ g
calcipotriol sandoz 50 mikrog/ g
sandoz - københavn - kalsipotriol - salve - 50 mikrog/ g
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - legemidler til behandling av bein sykdommer - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.